ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Abstract Number: 0718

Obesity Impairs Achievement of Clinical Inactive Disease (CID) in Patients with Juvenile Idiopathic Arthritis (JIA) Treated with TNF Inhibitors
Abstract Number: 0196

Objectively-Measured Obstructive Sleep Apnea Is Frequent Among Individuals with Rheumatoid Arthritis
Abstract Number: 1642

Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
Abstract Number: 1765

Obstetric Outcomes in Younger Women Less Than 21 Years of Age Compared to Women Between Age 21 and 25 Years with Rheumatic Disease
Abstract Number: 1501

Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria
Abstract Number: 0944

Obstructive Sleep Apnea in Fibromyalgia Patients: A Meta-analysis
Abstract Number: 1036

Ocular Involvement and Treatment in Sarcodosis. Study of 41 Patients of a Series of 383 Patients from a Single University Hospital
Abstract Number: 1044

Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center
Abstract Number: 1043

Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center
Abstract Number: 2011

Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study
Abstract Number: 1921

Ongoing Vascular 18F-FDG Uptake Despite Clinical Remission in Patients Receiving Tocilizumab for Large Vessel Vasculitis-Giant Cell Arteritis: Single Universitary Center Experience of 30 Patients
Abstract Number: PP06

Only in My Dreams Can I Do the Things I Used to Do: Where There Is Research, There Is Hope
Abstract Number: 1566

Onset and Disease Course of Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitor Therapy at a Single Institution
Abstract Number: 1281

Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus
Abstract Number: 0402

Optical Coherence Tomography of the Skin Detects Scleroderma Changes in Clinically Unaffected Skin: An Opportunity for Early Detection of Systemic Sclerosis
Abstract Number: 1553

Optical Tomography Can Accurately Diagnose Lupus Arthritis
Abstract Number: 0833

Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics
Abstract Number: 1021

Organ Damage in Systemic Lupus Erythematosus Is Attributable More to Comorbidity (Hypertension) and Less to Socioeconomic Status
Abstract Number: 0389

Organ Specific Treatment Patterns of a Real-World, Electronic Health Record Cohort of Patients with Systemic Sclerosis
Abstract Number: 0931

Oropharyngeal Dysfunction in Patients with Systemic Sclerosis – Results of a Monocentric Clinical Study
Abstract Number: 1122

Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review
Abstract Number: 1121

Osteoarthritis in the Million Veterans Program: Integrating the Electronic Medical Record with Precision Medicine
Abstract Number: 1110

Osteoarthritis-Related Knee Inflammation Measured by Ultrasound Is Associated with Performance-Based Measures of Function
Abstract Number: 0122

Osteoporosis Medication Utilization Patterns over Time in the ACR RISE Registry
Abstract Number: 0321

Outcome Measures in Psoriatic Arthritis Registries Are Very Heterogeneous: A Systematic Literature Review of 27 Registries, or 16183 Patients
Abstract Number: 1941

Outcome of Giant Cell Arteritis Patients Who Were Primarily Admitted for Venous Thromboembolism Events
Abstract Number: 1841

Outcomes After Hydroxychloroquine Reduction or Discontinuation in a Multinational Inception Cohort of Systemic Lupus
Abstract Number: 1226

Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK
Abstract Number: 0668

Outcomes and Resource Utilization After Total Knee Arthroplasty in Calcium Pyrophosphate Crystal Deposition Disease Patients: Insights from the National Inpatient Sample Database
Abstract Number: 0983

Outcomes Following Antimalarial Withdrawal in Patients with Quiescent Systemic Lupus Erythematosus
Abstract Number: 1496

Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome
Abstract Number: 0430

Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center Research Network
Abstract Number: L01

Outcomes of COVID-19 Infection in Patients with Rheumatic Diseases in a Multicenter Healthcare System: A Comparative Cohort Study
Abstract Number: 1424

Outcomes of Hospitalizations for Acute Myocardial Infarction in Patients with ANCA Associated Vasculitis from the National Inpatient Sample
Abstract Number: 0400

Outcomes of Systemic Sclerosis Hospitalizations by Hospital Teaching Status: Analysis of the National Inpatient Sample
Abstract Number: 1390

Outcomes of Systemic Sclerosis Patients Who Were Primarily Admitted for Acute Myocardial Infarction from 2016 to 2017: Insights from the National Inpatient Sample
Abstract Number: 1019

Outdoor Air Pollution and Systemic Lupus Erythematosus
Abstract Number: 1574

Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review
Abstract Number: 0284

Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-induced Lupus Model
Abstract Number: 0318

Oxylipin Profile Is Associated with Skin Disease and Enthesitis in Psoriatic Disease
Abstract Number: 0970

Oxylipins Profiles During the Earliest Phases of Rheumatoid Arthritis: Associations with Clinical Stage and Treatment Outcomes

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].